Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.

2.50
Hdl Handle:
http://hdl.handle.net/10146/232071
Title:
Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.
Authors:
Steinbrecher, Astrid; Méplan, Catherine; Hesketh, John; Schomburg, Lutz; Endermann, Tobias; Jansen, Eugene; Akesson, Bjorn; Rohrmann, Sabine; Linseisen, Jakob
Abstract:
Evidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.; A case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).; The OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).; Our results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.; These findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.
Citation:
Cancer Epidemiol. Biomarkers Prev. 2010, 19 (11):2958-2968
Journal:
Cancer Epidemiology, Biomarkers & Prevention
Issue Date:
Nov-2010
URI:
http://hdl.handle.net/10146/232071
DOI:
10.1158/1055-9965.EPI-10-0364
PubMed ID:
20852007
Additional Links:
http://cebp.aacrjournals.org/content/19/11/2958.long
Type:
Article
Language:
en
ISSN:
1538-7755
Sponsors:
The following authors have membership on EU NoE, which was instrumental in the initiation of the study: J. Linseisen, S. Rohrmann (ECNIS), J. Hesketh (NuGO), and B. Åkesson (NuGO, ECNIS).
Appears in Collections:
Articles

Full metadata record

DC FieldValue Language
dc.contributor.authorSteinbrecher, Astriden_GB
dc.contributor.authorMéplan, Catherineen_GB
dc.contributor.authorHesketh, Johnen_GB
dc.contributor.authorSchomburg, Lutzen_GB
dc.contributor.authorEndermann, Tobiasen_GB
dc.contributor.authorJansen, Eugeneen_GB
dc.contributor.authorAkesson, Bjornen_GB
dc.contributor.authorRohrmann, Sabineen_GB
dc.contributor.authorLinseisen, Jakoben_GB
dc.date.accessioned2012-07-04T09:32:26Z-
dc.date.available2012-07-04T09:32:26Z-
dc.date.issued2010-11-
dc.identifier.citationCancer Epidemiol. Biomarkers Prev. 2010, 19 (11):2958-2968en_GB
dc.identifier.issn1538-7755-
dc.identifier.pmid20852007-
dc.identifier.doi10.1158/1055-9965.EPI-10-0364-
dc.identifier.urihttp://hdl.handle.net/10146/232071-
dc.description.abstractEvidence for an association between selenium status and prostate cancer risk is still inconclusive. Anticarcinogenic effects of selenium are supposedly mediated through cellular protective and redox properties of selenoenzymes in vivo. We evaluated the association between serum selenium status and prostate cancer risk in a population with relative low selenium concentrations considering effect modification by genetic variants in selenoprotein genes.en_GB
dc.description.abstractA case-control study of 248 incident prostate cancer cases and 492 matched controls was nested within the EPIC-Heidelberg cohort. Baseline blood samples were analyzed for serum selenium and selenoprotein P concentrations and glutathione peroxidase activity. Genotyping was carried out for SEP15 (rs5859, rs540049), SEPP1 (rs3877899, rs7579), GPX1 (rs1050450), and GPX4 (rs713041). Conditional logistic regression was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (95% CI).en_GB
dc.description.abstractThe OR for prostate cancer was 0.89 (95% CI, 0.79-1.01) per 10 μg/L increase of serum selenium concentration. This association was modified by rs1050450 (C>T) in GPX1 (P(interaction) = 0.03), with carriers of one or two T alleles having a significantly reduced OR of 0.87 (95% CI, 0.76-0.99). Furthermore, there was an association between rs7579 genotype in SEPP1 and prostate cancer risk (OR, 1.72; 95% CI, 0.99-2.98).en_GB
dc.description.abstractOur results support a role of selenium and polymorphisms in selenoenzymes in prostate cancer etiology, which warrants confirmation in future studies.en_GB
dc.description.abstractThese findings might help to explain biological effects of selenium in prostate cancer development in order to overcome inconsistencies arising from former studies.en_GB
dc.description.sponsorshipThe following authors have membership on EU NoE, which was instrumental in the initiation of the study: J. Linseisen, S. Rohrmann (ECNIS), J. Hesketh (NuGO), and B. Åkesson (NuGO, ECNIS).en_GB
dc.language.isoenen
dc.relation.urlhttp://cebp.aacrjournals.org/content/19/11/2958.longen_GB
dc.rightsArchived with thanks to Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncologyen_GB
dc.subjectProstate canceren_GB
dc.subjectCancer risken_GB
dc.subjectSeleniumen_GB
dc.subjectSelenoproteinsen_GB
dc.subjectGenotypeen_GB
dc.subjectGlutathione Peroxidaseen_GB
dc.subjectPolymorphismen_GB
dc.subjectHumansen_GB
dc.subjectRisk Factorsen_GB
dc.subjectCase-Control Studiesen_GB
dc.subjectOdds Ratioen_GB
dc.subjectEuropeen_GB
dc.subject.meshAdult-
dc.subject.meshCase-Control Studies-
dc.subject.meshEurope-
dc.subject.meshGenetic Predisposition to Disease-
dc.subject.meshGenotype-
dc.subject.meshGlutathione Peroxidase-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOdds Ratio-
dc.subject.meshPolymorphism, Single Nucleotide-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshRisk Factors-
dc.subject.meshSelenium-
dc.subject.meshSelenoproteins-
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization-
dc.titleEffects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men.en
dc.typeArticleen
dc.identifier.journalCancer Epidemiology, Biomarkers & Preventionen_GB

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.